EAN 2025: Early Add-On Therapy Shows Benefit in Myasthenia Gravis

Dr. Menekse Öztürk, a Neurology Resident at BG University Hospital Bergmannsheil, Germany, presents preliminary data from a multicentre real-world cohort study on treatment timing in generalised myasthenia gravis. Patients who received early add-on therapy, within 24 months of diagnosis, showed trends toward better clinical outcomes, improved quality of life, and more efficient steroid tapering.